$CNSY

CYTORI THERAPEUTICS, INC.

CIK:0001095981|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue	$ 411	$ 1,390	$ 1,439	$ 2,449
Revenue, Product and Service [Extensible Enumeration]	Grant [Member]	Grant [Member]	Grant [Member]	Grant [Member]
Operating expenses:
Research and development	$ 4,265	$ 1,246	$ 7,130	$ 3,002
General and administrative	5,203	1,682	10,485	4,521
Total operating expenses	9,468	2,928	17,615	7,523
Operating loss	(9,057)	(1,538)	(16,176)	(5,074)
Other income (expense):
Interest income	56	27	246	28
Interest expense	(5)		(22)	(548)
Financing expenses		150		(3,061)
Warrant issuance costs				(964)
Change in fair value of derivative instruments		6,512		(2,631)
Total other income (expense)	51	6,689	224	(7,176)
Net income (loss)	$ (9,006)	$ 5,151	$ (15,952)	$ (12,250)
Net income (loss) per share of common stock - basic	$ (1.31)	$ 0.62	$ (2.36)	$ (12.54)
Weighted average number of shares of common stock outstanding - basic	6,898,804	1,935,554	6,773,125	976,885
Net loss per share of common stock - diluted	$ (1.31)	$ (0.16)	$ (2.36)	$ (12.54)
Weighted average number of shares of common stock outstanding - diluted	6,898,804	8,366,199	6,773,125	976,885

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (15,952)	$ (12,250)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	233	223
Stock-based compensation expense	1,852	300
Noncash financing expenses		3,061
Noncash interest expense	22
Change in fair value of derivative instruments		2,631
Accretion of discount on short-term investments	(15)	(22)
Operating lease right-of-use asset amortization	27	44
Gain on sale of assets		(16)
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Grant receivable	(1,439)	(450)
Other assets	264	(265)
Accounts payable and accrued expenses	1,778	(5,181)
Change in operating lease liabilities	(27)	(45)
Other liabilities	(113)
Net cash used in operating activities	(13,370)	(11,970)
Cash flows from investing activities:
Purchases of property and equipment	(1,317)	(10)
Proceeds from sale of property and equipment		30
Purchase of short-term investments	(14,049)	(7,756)
Sales of short-term investments	7,765
Redemption of short-term investments	4,434	6,662
Net cash used in investing activities	(3,167)	(1,074)
Cash flows from financing activities:
Proceeds from credit facility	1,000
Repayment of credit facility	(1,772)	(3,292)
Proceeds from issuance of notes payable and warrants		3,738
Repayment of notes payable		(3,703)
Proceeds from sale of common stock, pre-funded warrants and warrants		15,001
Proceeds from exercise of warrants		882
Proceeds from sale of common stock under Lincoln Park Purchase Agreement		2,795
Proceeds from underwritten public offering	15,000
Proceeds from Distribution Agreement	1,853
Payments for commissions and offering costs from Distribution Agreement	(71)
Payment to investors pursuant to Letter Agreement	(4,502)
Offering costs for sale of common stock	(1,363)	(220)
Net cash provided by financing activities	10,145	15,201
Net change in cash and cash equivalents	(6,392)	2,157
Cash, restricted cash and cash equivalents at beginning of period	8,758	76
Cash, restricted cash and cash equivalents at end of period	2,366	2,233
Cash paid during period for:
Interest		539
Supplemental schedule of non-cash investing and financing activities:
Exchange of warrants for notes payable		3,694
Redemption of notes by issuance of common stock, pre-funded warrants and warrants		3,512
Unpaid offering cost	$ 104	$ 252

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 2,366		$ 4,256
Restricted cash and cash equivalents			4,502
Investments	6,221		4,356
Grant receivable	1,761		322
Other current assets	1,423		1,734
Total current assets	11,771		15,170
Property and equipment, net	1,409		257
Operating lease right-of-use assets	43		70
Goodwill	372		372
Intangible assets, net	265		333
Other assets	170		123
Total assets	14,030		16,325
Current liabilities:
Accounts payable and accrued expenses	7,550		5,920
Investor liability pursuant to Letter Agreement			4,502
Operating lease liability	44		56
Deferred grant liability	927		927
Line of credit	0		750
Other liabilities	46		159
Total current liabilities	8,567		12,314
Noncurrent operating lease liability			15
Total liabilities	8,567		12,329
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value; 2,000,000,000 shares authorized; 7,320,345 and 5,557,371 shares issued as of June 30, 2026 and December 31, 2025, respectively; 7,310,008 and 5,547,034 shares outstanding as of June 30, 2026 and December 31, 2025, respectively	7		6
Treasury stock (at cost), 10,337 shares as of June 30, 2026 and December 31, 2025, respectively	(500)		(500)
Additional paid-in capital	537,773		520,355
Accumulated deficit	(531,817)		(515,865)
Total stockholders' equity	5,463	$ 11,961	3,996
Total liabilities and stockholders' equity	$ 14,030		$ 16,325